Home / Explore Insights / Phase I Evaluation of the Safety and Pharmacokinetics of Murine-derived Anticryptococcal Antibody 18B7 in Subjects with Treated Cryptococcal Meningitis
/ Insights / Explore Insights / Phase I Evaluation of the Safety and Pharmacokinetics of Murine-derived Anticryptococcal Antibody 18B7 in Subjects with Treated Cryptococcal Meningitis
Phase I Evaluation of the Safety and Pharmacokinetics of Murine-derived Anticryptococcal Antibody 18B7 in Subjects with Treated Cryptococcal Meningitis
Larsen RA, Pappas PG, Perfect J, et al.
Antimicrobial Agents and Chemotherapy
BAMSG/BAMBU
02/28/2005
Publication
